Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $945.00 | 2 | 55.2% |
| Education | $383.20 | 5 | 22.4% |
| Food and Beverage | $382.93 | 4 | 22.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARRAY BIOPHARMA INC | $1,048 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $193.77 | 2 | $0 (2019) |
| Astellas Pharma US Inc | $159.98 | 2 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $86.24 | 1 | $0 (2018) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $86.21 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $71.99 | 1 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $64.99 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,048 | 3 | ARRAY BIOPHARMA INC ($1,048) |
| 2019 | $476.95 | 6 | E.R. Squibb & Sons, L.L.C. ($193.77) |
| 2018 | $186.23 | 2 | Astellas Pharma US Inc ($99.99) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/24/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $315.00 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $630.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $86.21 | General |
| 08/16/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $71.99 | General |
| Category: Oncology | ||||||
| 08/09/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $84.89 | General |
| Category: Oncology | ||||||
| 08/08/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $108.88 | General |
| 07/25/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $59.99 | General |
| 04/11/2019 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Education | In-kind items and services | $64.99 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 10/17/2018 | Takeda Pharmaceuticals U.S.A., Inc. | VELCADE (Drug) | Education | In-kind items and services | $86.24 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 165 | 290 | $173,914 | $29,190 |
| 2022 | 4 | 93 | 163 | $104,467 | $19,417 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 50 | 118 | $82,565 | $13,825 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 32 | 32 | $27,922 | $4,747 | 17.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 45 | $15,868 | $2,831 | 17.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 37 | $19,570 | $2,745 | 14.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 20 | 32 | $13,072 | $2,497 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 15 | $10,770 | $1,838 | 17.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $4,147 | $707.82 | 17.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 26 | 70 | $50,064 | $8,759 | 17.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 37 | 37 | $32,011 | $5,823 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 33 | $13,215 | $2,813 | 21.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 23 | $9,177 | $2,021 | 22.0% |
About Dr. Tamara Sussman, M.D
Dr. Tamara Sussman, M.D is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/22/2015. The National Provider Identifier (NPI) number assigned to this provider is 1427445097.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tamara Sussman, M.D has received a total of $1,711 in payments from pharmaceutical and medical device companies, with $1,048 received in 2023. These payments were reported across 11 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($945.00).
As a Medicare-enrolled provider, Sussman has provided services to 258 Medicare beneficiaries, totaling 453 services with total Medicare billing of $48,607. Data is available for 2 years (2022–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Medical Oncology
- Location Boston, MA
- Active Since 04/22/2015
- Last Updated 07/13/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427445097
Products in Payments
- BRAFTOVI (Drug) $945.00
- MEKTOVI (Drug) $102.95
- VELCADE (Drug) $86.24
- OPDIVO (Biological) $84.89
- IMBRUVICA (Drug) $71.99
- JEVTANA (Drug) $64.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M